Jure Murgic

Dr. Jure Murgic

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
Dimitra Rafailia BakaloudiDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
RTRafee Talukder
Rafee Talukder
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
DMDimitrios Makrakis
Dimitrios Makrakis
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
PGPetros Grivas
Petros Grivas

20 February 2022 in Genes
Verified
Journal Article
Open access
PDF file
SLSven Ljubić
Sven Ljubić
ASAntonio Sermek
Antonio Sermek
ASAngela Prgomet Sečan
Angela Prgomet Sečan
MPMarin Prpic
Marin Prpic
BJBlanka Jakšić
Blanka Jakšić
Isidoro FelicielloIsidoro Feliciello
Isidoro Feliciello
The aberrant overexpression of alpha satellite DNA is characteristic of many human cancers including prostate cancer; however, it is not known whether the change in the alpha satellite RNA amount occurs in the peripheral tissues of cancer patients, such as blood. Here, we analyse the level of intracellular alpha satellite RNA in the whole blood of cancer prostate patients at different stages of disease and compare it with the levels found in healthy controls. Our results reveal a significantly increased level of intracellular alpha satellite RNA in the blood of metastatic cancers patients, particularly those with metastatic castration-resistant prostate cancer relative to controls. In the blood of patients with localised tumour, no significant change relative to the controls was detected. Our results show a link between prostate cancer pathogenesis and blood intracellular alpha satellite RNA levels. We discuss the possible mechanism which could lead to the increased level of blood intracellular alpha satellite RNA at a specific metastatic stage of prostate cancer. Additionally, we analyse the clinically accepted prostate cancer biomarker PSA in all samples and discuss the possibility that alpha satellite RNA can serve as a novel prostate cancer diagnostic blood biomarker.

1 June 2022 in European Urology Oncology
Verified
Journal Article
Closed access
HBHarry C. Brastianos
Harry C. Brastianos
JMJure Murgic
Jure Murgic
ASAdriana Salcedo
Adriana Salcedo
MCMelvin L.K. Chua
Melvin L.K. Chua
AMAlice Meng
Alice Meng
ABAlejandro Berlin
Alejandro Berlin

3 November 2023 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
RTRobert Terlević
Robert Terlević
MUMonika Ulamec
Monika Ulamec
GŠGoran Štimac
Goran Štimac
JMJure Murgic
Jure Murgic
BKBožo Krušlin
Božo Krušlin
The choice of therapy for muscle-invasive bladder cancer (MIBC) could be influenced by the tumor’s molecular subtype. Currently, well-defined consensus subtypes are based on tumor microarray mRNA data. Clearly defined and easy-to-use surrogate molecular subtypes, based on immunohistochemistry (IHC) performed on whole slides, are needed to make subtyping cost-effective and useful in routine work and future research. To aid in the development of a simple immunohistochemical classifier, a retrospective single-center series of 92 cases of localized bladder cancer was identified. Routine IHC for GATA3, cytokeratins 5 and 6 (CK5/6), and p16 was performed on whole tissue blocks containing muscle-invasive disease. Electronic medical records were retrieved and searched for clinical variables, treatment, and survival data. The mean age was 69.6 years, and 73% were males. Conservative treatment was used in 55% of cases, while cystectomy with chemotherapy was used in 45%. GATA3 and CK5/6 expression divided cases into broad luminal and basal subtypes, respectively, while p16 expression was used to subclassify luminal cases into luminal papillary and luminal unstable types according to the consensus molecular classification. When subtyped in this way, GATA3 and CK5/6 negative cases showed worse overall survival. Molecular subtyping of MIBC on whole slides containing muscle-invasive tumor using only three commonly used, consensus-based antibodies, is a feasible and cost-effective method for detecting subtypes of invasive bladder cancer. Future work combining morphological analysis and IHC is needed to fully translate the consensus molecular classification into a comprehensive, cost-effective subtyping strategy.

12 August 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
Dimitra Rafailia BakaloudiDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
RTRafee Talukder
Rafee Talukder
DMDimitrios Makrakis
Dimitrios Makrakis
LDLeonidas Diamantopoulos
Leonidas Diamantopoulos
TEThomas Enright
Thomas Enright
AKAli Raza Khaki
Ali Raza Khaki

1 June 2014
Verified
Journal Article
Closed access
DKDavor Kust
Davor Kust
MPMarin Prpic
Marin Prpic
JMJure Murgic
Jure Murgic
MJMarijana Jazvić
Marijana Jazvić
BJBlanka Jakšić
Blanka Jakšić
ZKZvonko Kusić
Zvonko Kusić